Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 studyKohei Shitara, Yung‐Jue Bang, Hisateru Yasui et al.|The Lancet Oncology|2023Cited by 336
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trialCharles S. Fuchs, Francesco Di Costanzo, Kohei Shitara et al.|The Lancet Oncology|2019Cited by 282
An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancerDaniel Morgensztern, Pilar Garrido, Nina Karaseva et al.|Lung Cancer|2019Cited by 24